HCV ADVOCATE WEEKLY NEWS REVIEW

[Guest guest]

HCV ADVOCATE WEEKLY NEWS REVIEW

Week Ending: April 24, 2010

This Issue:

Telbivudine Improves Survival over Lamivudine in Cirrhotic Patients with Hepatitis B Virus: Presented at EASL 2010 Needle Exchange Programs Are Working; Need Support Warehoused Hepatitis C Patients May Boost Merck, J & J (Update1) UPDATE 1-Gilead Stops Mid-Stage Trial of Hepatitis Treatment Hepatitis Awareness Organization Educates East Bay Community World Hepatitis Alliance Releases Major Report on Viral Hepatitis Policy at EASL Meeting Roche's Progress of RG7348 Into Phase I Clinical Trial Triggers $6.5M Milestone Payment to Ligand Dark Chocolate May Cure Liver Disorders Doctor Testifies in Hepatitis C Trial Bristol Compound Potent against Hepatitis C UPDATE 2-Vertex to Begin Telaprevir Application This Summer LG Life Reels as US Drug Trial Halts Tarmogen Vaccine Boosts Virological Response to Standard Treatment for Hepatitis C: Presented at EASL 500 Patients Get Warning About Chance of Infection From Testing Needle Exchange Advocates Say HIV Rates in Canadian Prisons Outstrip the World

http://www.hcvadvocate.org/news/newsRev/2010/NewsRev-358.html